Galectin Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Galectin Therapeutics

16/08/2021 15:34

* Galectin Therapeutics Inc  GALT.OQ  reported a quarterly
adjusted loss of 14 cents​​ per share for the quarter ended in
June. The lone analyst forecast for the quarter was for a loss
of 18 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Galectin Therapeutics Inc's reported EPS for the quarter was a
loss of 15 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Galectin Therapeutics Inc shares had risen by 5.6% this
quarter and gained 50.9% so far this year.
* The company reported a quarterly loss of $8.51 million.
* Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $14.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 16 at 02:34 p.m.  ​All
figures in US dollars unless otherwise stated